The identification of STARD10 as a key player in HER2+ breast cancer progression and lipid metabolism presents a significant opportunity for pharmaceutical companies to innovate new therapeutic strategies. This could reshape treatment paradigms and enhance competitive positioning in the oncology market. Regulatory context from FDA (FDA AP — ONTRUZANT (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).